BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30431119)

  • 1. Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
    Zou M; Hu X; Xu B; Tong T; Jing Y; Xi L; Zhou W; Lu J; Wang X; Yang X; Liao F
    Oncol Rep; 2019 Feb; 41(2):989-998. PubMed ID: 30431119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W; Wang J; Man WY; Zhang QW; Xu WG
    Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
    Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
    Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Zhang T; Guan M; Jin HY; Lu Y
    Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
    Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
    Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
    He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
    Xu L; Zhang B; Li W
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):126-34. PubMed ID: 26917482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
    Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
    Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
    Teng X; Wang SY; Shi YQ; Fan XF; Liu S; Xing Y; Guo YY; Dong M
    Anticancer Drugs; 2021 Oct; 32(9):939-949. PubMed ID: 34001704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
    Zhang W; Wu FX; Wang Q; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
    Zhang TM
    Chemotherapy; 2019; 64(3):119-128. PubMed ID: 31661694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The roles of holothurian glycosaminoglycan combined with cisplatin on proliferation and chemotherapeutic response in A549 human lung adenocarcinoma cell].
    Jin Q; Zhu XH; Lin CZ; Zhang H; Cao YW; Ding XQ; Lyu ZH
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):252-257. PubMed ID: 29730910
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
    Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
    PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.